Dallas, TX -- (ReleaseWire) -- 03/17/2014 -- Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics.
Analysts forecast the Global Dermatological Drug market to grow at a CAGR of 4.29 percent over the period 2013-2018. According to the report, one of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis.
The Global Dermatological Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Dermatological Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders.
The report recognizes the following companies as the key players in Global Dermatological Drugs Market: AbbVie Inc., Galderma S.A., Johnson & Johnson Ltd., Novartis AG, Stiefel Laboratories Inc., Valeant Pharmaceuticals International Inc., Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA.
Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=276792.
Other vendors mentioned in the report are Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA.
Key questions answered in this report:
- What will the market size and growth rate be in 2018?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by key vendors?
- What are the strengths and weaknesses of each of these key vendors?